Johns Hopkins scientists develop nose spray DNA vaccine for tuberculosis

Researchers at Johns Hopkins have created an innovative intranasal DNA vaccine aimed at combating tuberculosis, showing promise in animal studies by accelerating infection clearance, reducing lung inflammation, and preventing relapses. This new approach targets bacteria that evade traditional antibiotics, potentially enhancing the efficacy of existing TB drugs, especially those for drug-resistant strains. The implications are significant, offering a potential breakthrough in TB treatment that could drastically improve outcomes and reduce the global burden of this persistent disease.